3D-printed bones are a step closer after two ASX-listed medtechs won part of a $10 million windfall from the federal government’s $35 million BioMedTech Horizons program.

Health minister Greg Hunt today announced the program’s first 11 recipients including Allegra Orthopaedics (ASX:AMT) and Orthocell (ASX: OCC).

Investments from the program — which is part of the $20 billion federal Medical Research Future Fund — are focused on precision medicine and 3D anatomical printing.

Allegra Orthopaedics (ASX:AMT) got the nod for its spinal cage printed from synthetic bone bioceramic.

The device works to regenerate bone under spinal load conditions before being completely resorbed by the body leaving no foreign materials.

It is 3D-printed from a synthetic material (‘Sr-HT-Gahnite’) invented by the University of Sydney and licensed to Allegra.

Allegra said the grant will help to provide for the device to go from idea to production for preclinical testing.

Fellow recipient Orthocell (ASX: OCC) is making a personalised bone-ligament-bone graft using 3D printed scaffolds for sufferers of wrist ligament injuries.

Last month, its collagen rope Cellgro received positive results in preclinical testing for use in ACL injuries.

“Our researchers are innovators and this investment will speed up the journey from idea to reality,” Mr  Hunt said at the ceremony.

“These technologies have the potential to create better health outcomes for Australians, while driving investment and strengthening our economy. All Australians benefit from investment in health and medical research.”

The winning projects beat out 219 expressions of interest submitted – making them some of the best in the space.